Literature DB >> 9588549

Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors.

R Sawaya1, M Hammoud, D Schoppa, K R Hess, S Z Wu, W M Shi, D M Wildrick.   

Abstract

OBJECTIVE: The goals were to critically review all complications resulting within 30 days after craniotomies performed for excision of intra-axial brain tumors relative to factors likely to affect complication rates and to assess the value of these data in predicting the risk of surgical morbidity, particularly for surgery in eloquent brain regions.
METHODS: Neurosurgical outcomes were studied for 327 patients who underwent 400 craniotomies for removal of intra-axial parenchymal brain neoplasms in a 21-month period. Tumors removed included gliomas (206 tumors) and metastases (194 tumors) located both supratentorially (358 tumors) and infratentorially (42 tumors).
RESULTS: The major complication incidence was 13%, and the operative mortality rate was 1.7%. The overall morbidity rate was 32%, but more types of complications were considered than in previous studies. The major neurological morbidity rate was 8.5%. Based on pre- versus postoperative (at 4 wk) Karnofsky Performance Scale scores, 9% of patients deteriorated neurologically, 32% improved, and 58% showed no change. The median postoperative hospital stay was 5 days. Tumors were defined as Grade I, II, or III based on their location relative to brain function, and this tumor functional grade was the most important variable affecting the incidence of any neurological deficit. Patients with tumors in eloquent (Grade III) or near-eloquent (Grade II) brain areas incurred more neurological deficits than did patients with tumors in noneloquent areas (Grade I). Neither repeat surgery for recurrent disease nor extent of surgical resection affected outcome significantly. Although most tumors in this study, including those in eloquent regions, were removed by gross total resection, this did not lead to more major neurological deficits. Regional complications (at the surgical sites) and systemic complications (medical) were more prevalent among older patients (age >60 yr) with lower preoperative Karnofsky Performance Scale scores (< or = 50) and posterior fossa masses. We showed how our data can be used to predict the total risk of surgical morbidity for a given patient, to facilitate patient counseling and surgical decision-making.
CONCLUSION: The finding that gross total resections could be performed in eloquent brain regions with an acceptable level of neurological impairment suggested that the mere presence of a tumor in eloquent brain does not automatically contraindicate surgery. Our results have practical risk-predictive value, and they should aid in the construction of subsequent outcome studies, because we have identified the key areas to monitor.

Entities:  

Mesh:

Year:  1998        PMID: 9588549     DOI: 10.1097/00006123-199805000-00054

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  156 in total

1.  Extent of resection in malignant gliomas: a critical summary.

Authors:  R Sawaya
Journal:  J Neurooncol       Date:  1999-05       Impact factor: 4.130

2.  Functional recovery after surgical resection of low grade gliomas in eloquent brain: hypothesis of brain compensation.

Authors:  H Duffau; L Capelle; D Denvil; N Sichez; P Gatignol; M Lopes; M-C Mitchell; J-P Sichez; R Van Effenterre
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-07       Impact factor: 10.154

3.  Significance of target location relative to the depth from the brain surface and high-dose irradiated volume in the development of brain radionecrosis after micromultileaf collimator-based stereotactic radiosurgery for brain metastases.

Authors:  Kazuhiro Ohtakara; Shinya Hayashi; Noriyuki Nakayama; Naoyuki Ohe; Hirohito Yano; Toru Iwama; Hiroaki Hoshi
Journal:  J Neurooncol       Date:  2012-03-06       Impact factor: 4.130

4.  Effect of 10 different polymorphisms on preoperative volumetric characteristics of glioblastoma multiforme.

Authors:  Christian Henker; Thomas Kriesen; Katharina Fürst; Deborah Goody; Änne Glass; Brigitte M Pützer; Jürgen Piek
Journal:  J Neurooncol       Date:  2015-11-25       Impact factor: 4.130

5.  The benefit of surgical resection in recurrent glioblastoma.

Authors:  Michael A Vogelbaum
Journal:  Neuro Oncol       Date:  2016-02-10       Impact factor: 12.300

6.  Neurocognitive Changes Associated With Surgical Resection of Left and Right Temporal Lobe Glioma.

Authors:  Kyle R Noll; Jeffrey S Weinberg; Mateo Ziu; Ronald J Benveniste; Dima Suki; Jeffrey S Wefel
Journal:  Neurosurgery       Date:  2015-11       Impact factor: 4.654

7.  Central nervous system cancers.

Authors:  Louis Burt Nabors; Mario Ammirati; Philip J Bierman; Henry Brem; Nicholas Butowski; Marc C Chamberlain; Lisa M DeAngelis; Robert A Fenstermaker; Allan Friedman; Mark R Gilbert; Deneen Hesser; Matthias Holdhoff; Larry Junck; Ronald Lawson; Jay S Loeffler; Moshe H Maor; Paul L Moots; Tara Morrison; Maciej M Mrugala; Herbert B Newton; Jana Portnow; Jeffrey J Raizer; Lawrence Recht; Dennis C Shrieve; Allen K Sills; David Tran; Nam Tran; Frank D Vrionis; Patrick Y Wen; Nicole McMillian; Maria Ho
Journal:  J Natl Compr Canc Netw       Date:  2013-09-01       Impact factor: 11.908

8.  Operative treatment of subcortical metastatic tumours in the central region.

Authors:  J Walter; S A Kuhn; A Waschke; R Kalff; C Ewald
Journal:  J Neurooncol       Date:  2010-09-29       Impact factor: 4.130

9.  Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma.

Authors:  Kaisorn L Chaichana; Ignacio Jusue-Torres; Rodrigo Navarro-Ramirez; Shaan M Raza; Maria Pascual-Gallego; Aly Ibrahim; Marta Hernandez-Hermann; Luis Gomez; Xiaobu Ye; Jon D Weingart; Alessandro Olivi; Jaishri Blakeley; Gary L Gallia; Michael Lim; Henry Brem; Alfredo Quinones-Hinojosa
Journal:  Neuro Oncol       Date:  2013-11-26       Impact factor: 12.300

10.  Outcome of patients affected by newly diagnosed glioblastoma undergoing surgery assisted by 5-aminolevulinic acid guided resection followed by BCNU wafers implantation: a 3-year follow-up.

Authors:  Alessandro Della Puppa; Giuseppe Lombardi; Marta Rossetto; Oriela Rustemi; Franco Berti; Diego Cecchin; Marina Paola Gardiman; Giuseppe Rolma; Luca Persano; Vittorina Zagonel; Renato Scienza
Journal:  J Neurooncol       Date:  2016-10-18       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.